Amgen Medical Director - US Medical Lead - Leukemia Assets in Thousand Oaks, California
The US Medical Lead for the Leukemia Assets, is accountable for the development and implementation of the US medical affairs strategy for Amgen’s assets in Acute Leukemia. Through cross-functional collaboration and deep understanding of the treatment landscape, the medical lead will provide strategic direction in the development of the US medical plans including external engagement, communication and evidence generation strategies and contribute to the overall global product strategy.
We need collaborative and innovative world-class talent to ensure these molecules become medicines and that they will strive to reach their full potential while helping patients.
The key responsibilities for this role are:
Develop and implement the US medical strategy for the Leukemia assets via the US Medical Plan, including launch preparation and lifecycle management support.
Develop a comprehensive US medical plan for the Leukemia assets, including external stakeholder management, scientific communications, evidence generation and medical education strategy
Contribute to the US product strategy through deep understanding of the US medical environment, sharing insights through engagement with external experts
Facilitate and continue to build Amgen’s role as a science based and patient focused reliable partner
Partner with Global Development Leads and Global Medical Affairs Leads on evidence generation activities and ensuring the Evidence Generation Plan captures key regional needs
Facilitate scientific engagement across a broad range of stakeholders to strengthen external understanding of the unmet need and medical value of Amgen’s assets in AML
Collaborate with the Global Medical Affairs Lead on the development Potential Area of Scientific Interest (PASI) for Investigator Sponsored Studies (ISS) and review the study concept proposals submitted by US researchers
Provide strategic direction for study design and execution for local and global medical affairs studies
Enable access to medicines through clear understanding and education of treatment value in partnership with cross-functional stakeholders
Contribute to the development of medical communication strategy and related activities, e.g., product narrative, scientific platform, core content, publications, medical education, and congresses
Contribute to Amgen's Global Safety and global Benefit/Risk profile of a molecule and ensure communication of the implications to external stakeholders
Contribute to Advisory Board development and execution
Contribute to the development of the Global Value Dossier
Determine resource and budget allocation necessary to deliver on the US medical strategy
MD or DO degree from an accredited medical school OR PhD OR PharmD
2 years of Medical Affairs experiences and/or clinical research experience and/or basic science research in Hematology-Oncology
Clinical and disease knowledge base in hematological malignancies
MD plus accredited fellowship in Hematology-Oncology, board certified or board eligible
5+ years of Medical Affairs experience in the pharma/biotech industry
5+ years of patient clinical experience in AML
3+ years of clinical research experience in Hematology-Oncology
Management and leadership experience in a direct report and non-direct report framework with complex cross-functional responsibilities
Our recruitment strategy includes fostering diverse points of view – helping to drive innovation and creativity.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.